Pipeline Intelligence: The New Currency of Pharmaceutical Strategy

Pharma firms are more data empowered than ever before. New information is being gained daily through clinical trials, drug candidates, sponsors, biomarker development, and mechanisms of action, to name a few.

The difficulty is not just in finding data. The hard part is understanding which information is relevant and what each piece of data has to do with each other, and what it does for the next business move.

That's why pipeline intelligence is becoming a crucial component of the pharmaceutical strategy.

A clear drug pipeline is useful for companies to find emerging competitors, understand development risks, to identify potential licensing opportunities, and also for making better decisions on the portfolio. When the timeline for development is years long and investments can run billions of dollars, coming up with the right intelligence at the right time can have a great impact.

What Is Pharmaceutical Pipeline Intelligence?

Pharmaceutical pipeline intelligence is the process of gathering, linking and analyzing information related to drugs and development programs.

It involves more than just that a specific drug is in Phase II or phase III. A valuable intelligence consideration is the bigger picture:

• Who is doing the research and development of the drug?
• What is the barometer for this indication?
• How does the system function?
• How far along in the process of developing the drug is the program?
• What studies are being conducted at the moment?
• What other organizations are competing with the sponsors?
• What are the biomarkers or patient populations?
• Are there any partnerships or licensing activities announced by the company?
• What clinical development evidence is becoming available?

Once linked together, pipeline data becomes much more useful in the context of strategic decision making.

For instance, new insights gained from pipeline intelligence are more crucial than ever before.

Drug development is getting more and more complicated!

According to the FDA, drug development is a journey from discovery and preclinical research to clinical research, regulation review and post marketing surveillance.

The process generates various sources of information and strategic questions at each stage.

Meanwhile, pharmaceutical R&D timelines continue to be under pressure. According to IQVIA's Global R&D Trends Report for 2026, timelines for end-to-end clinical development are getting longer, and the industry's scientific complexity and productivity issues persist.

This means that the timely and accurate dissemination of intelligence takes on greater value.

Companies must be aware of the locations of their assets and what their competitors, new biotech firms and potential partners are working on.

Knowing the Pipeline Across Pharmaceutical Phases

Considering development programs through the various phases of the pharmaceutical journey adds value to pipeline intelligence.

Discovery & Preclinical Development

Early stage Intelligence can uncover new targets, molecules, technologies, and mechanisms of action.

At this point, it is not a time to take it for granted that every early program will be successful. Rather, businesses can track new scientific developments and pinpoint areas that could become key.

Phase I

Typically, the first phase of clinical trials involves safety, tolerability, dose and drug-human interactions.

The Phase I programs can give competitive intelligence teams a heads-up if a sponsor is interested in a new mechanism or therapeutic area.

Phase II

Phase II trials give further information on effectiveness and side effects, and help to guide further development.

It is a pivotal phase when companies start to provide more meaningful clinical evidence, an aspect that is crucial in comparison with other programs.

Phase III

The third phase of trials is typically larger and aims to yield more robust evidence of effectiveness and safety.

In the case of the portfolio and business development teams, keeping an eye on programs that are in or are on the verge of entering Phase III might be especially relevant due to the competitive and commercial considerations that come into play.

Phase IV

Post-approval studies may be used to give further information on safety and efficacy and may help to establish new indications or other lifecycle strategies.

The cross-over of these stages provides companies with a much clearer picture on how a therapeutic area is developing.

The transformative journey of turning data into actionable intelligence.The process of clinical trial data transforming into actionable intelligence.

One of the most important sources of pipeline information is clinical trials.

Information regarding the sponsor, intervention, indication, phase, study design, number of participants enrolled, endpoints, location, and status of the clinical trial can be recorded in the clinical trial record.

However, individual records are not always definitive.

What's truly valuable is joining several records and datasets together.

For example:

• The sequence of the drugs, sponsors, clinical trial, study phases, mechanism, biomarker, competitor, and outcome.

This holistic view can contribute to a company's understanding of the competition and how a drug fits in.

This is where today's clinical trial data solutions are relevant. Good solutions will not only provide access to a wealth of records, but facilitate searching, comparing, filtering and interpretation of clinical research information.

The ClinicalTrials.gov has also enhanced its structured data access capability with its modern API, which now allows programmers to access the clinical trial data.

The Contribution of APIs to Clinical Research

The more data pharmaceutical companies are using, the more critical it is to be able to connect systems.

API clinical research can enable the integration of structured clinical data from databases to research applications, analytics, and internal workflows.

This is important since intelligence teams are frequently required to relate clinical trial data to other data sets and not just one source.

For instance, a company can associate clinical trial information to:

• Drug pipeline information
• Sponsor intelligence
• Biomarker information
• Market data
• Competitive intelligence
• Internal portfolio information

That's where clinical API development can assist in scalable data integration.

The intention is not technology as an end in itself. The goal is to make relevant information easily accessible and usable, when teams are determining important development or business decisions.

Pipeline Is a Powerful Instrument That Can Reinforce a Competitive Strategy

The competition among pharmaceutical companies can begin well before the product is available for sale.

An indication entry into a new competitor in Phase II, an indication change in patient population and an indication start of a new clinical program can give a early indication of the competitor's strategy.

Companies can track pipeline use continually to develop insights into changes including:

• New clinical programs
• Phase transitions
• New indications
• Trial expansions
• New sponsors
• Biomarker strategies
• Discontinued programs
• Joint projects and licensing agreements

These signals can be used to determine the direction of a competitor's investment and the possible area of increased competition.

Importantly, pipeline intelligence should not be considered a crystal ball. It has the advantages of helping the team to identify signals and provide better assessment, but there is still a high uncertainty about clinical success and commercial results.

Evaluate Pipeline Intelligence and Licensing Opportunities

The business development and licensing teams are specifically benefitted by pipeline intelligence.

As the internal research and development capabilities of pharma companies wane, they are increasingly relying on external innovations. Despite the downturn, biopharma dealmaking activity continued to be robust in 2026, and deal activity has become more concentrated on differentiated assets and strategic fit into the portfolio, according to IQVIA.

This places greater emphasis on the need to be able to identify promising external programs.

Teams can keep an eye on earlier development programs and assess:

• Scientific rationale
• Development phase
• Clinical evidence
• Competitive positioning
• Sponsor capabilities
• Unmet medical need
• Potential differentiation
• Cooperation or licensing operations

It should not be a substitute for detailed due diligence, but rather a way to strengthen pipelines to investigate opportunities.

Why Connected Intelligence Is the True Advantage

Thousands of drug records are helpful. For example, suppose a company is looking into a particular therapeutic area. It might wish to learn:

• What drugs are being worked on?
• Who's working on them?
• What do we mean by these processes?
• Which types of clinical trials are being done at present?
• What are the quickest programs to advance?
• What assets might be licensed?
• Where are they putting their money these days?

These answers cannot be found in a standard drug database. It involves the integration of clinical, pipeline, sponsor, scientific and market intelligence.

That's why Pipeline Intelligence isn't just a research convenience anymore, it's a strategic capability.

Clival Database Helps in the Development of a Pharmaceutical Strategy

In the pharmaceutical and biotech space, the power of intelligence is in providing a more coherent picture of the market from the many pieces of information.

Clival Database provides clinical trial intelligence, drug pipeline information, sponsor intelligence, therapeutic-area analysis, biomarker and mechanism-of-action intelligence, competitive intelligence, investigator/site information and market intelligence.

This can be used to assist teams developing:

• Drug pipeline analysis
• Competitive intelligence
• Clinical development
• Portfolio strategy
• Business development
• Licensing opportunity identification
• Market research

Teams can consider the relationships between a drug, company and clinical trial instead of looking at them individually.

The connected view can help organizations be more data-driven and make decisions more quickly as competition in the pharmaceutical industry grows more data-driven.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!